eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | spondyloarthropathy |
| Comorbidity | C0030343|panuveitis |
| Sentences | 1 |
| PubMedID- 24359625 | Infliximab and adalimumab can be considered as potential second-line immunomodulatory agents for the treatment of severe ocular inflammatory conditions including posterior uveitis, panuveitis, severe uveitis associated with seronegative spondyloarthropathy, and scleritis in patients requiring immunomodulation in patients who have failed or who are not candidates for antimetabolite or calcineurin inhibitor immunomodulation. |
Page: 1